UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of $1.08 billion. The enterprise value is $1.08 billion.
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
UroGen Pharma has 46.81 million shares outstanding. The number of shares has increased by 18.43% in one year.
| Current Share Class | 46.81M |
| Shares Outstanding | 46.81M |
| Shares Change (YoY) | +18.43% |
| Shares Change (QoQ) | +0.67% |
| Owned by Insiders (%) | 2.12% |
| Owned by Institutions (%) | 80.51% |
| Float | 37.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.33 |
| Forward PS | 5.22 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.99
| Current Ratio | 3.99 |
| Quick Ratio | 3.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.56 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -33.96% |
| Return on Invested Capital (ROIC) | -101.59% |
| Return on Capital Employed (ROCE) | -92.65% |
| Revenue Per Employee | $410,706 |
| Profits Per Employee | -$700,604 |
| Employee Count | 235 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 1.46 |
Taxes
In the past 12 months, UroGen Pharma has paid $3.00 million in taxes.
| Income Tax | 3.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +84.43% in the last 52 weeks. The beta is 1.23, so UroGen Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | +84.43% |
| 50-Day Moving Average | 21.13 |
| 200-Day Moving Average | 15.15 |
| Relative Strength Index (RSI) | 45.87 |
| Average Volume (20 Days) | 1,162,267 |
Short Selling Information
The latest short interest is 8.98 million, so 19.18% of the outstanding shares have been sold short.
| Short Interest | 8.98M |
| Short Previous Month | 11.28M |
| Short % of Shares Out | 19.18% |
| Short % of Float | 24.22% |
| Short Ratio (days to cover) | 7.51 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of $96.52 million and -$164.64 million in losses. Loss per share was -$3.46.
| Revenue | 96.52M |
| Gross Profit | 84.89M |
| Operating Income | -132.31M |
| Pretax Income | -161.64M |
| Net Income | -164.64M |
| EBITDA | -131.11M |
| EBIT | -132.31M |
| Loss Per Share | -$3.46 |
Full Income StatementBalance Sheet
The company has $127.03 million in cash and $129.94 million in debt, giving a net cash position of -$2.53 million or -$0.05 per share.
| Cash & Cash Equivalents | 127.03M |
| Total Debt | 129.94M |
| Net Cash | -2.53M |
| Net Cash Per Share | -$0.05 |
| Equity (Book Value) | -115.41M |
| Book Value Per Share | -2.47 |
| Working Capital | 126.30M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$137.74 million and capital expenditures -$387,000, giving a free cash flow of -$138.13 million.
| Operating Cash Flow | -137.74M |
| Capital Expenditures | -387,000 |
| Free Cash Flow | -138.13M |
| FCF Per Share | -$2.95 |
Full Cash Flow StatementMargins
Gross margin is 87.95%, with operating and profit margins of -137.08% and -170.59%.
| Gross Margin | 87.95% |
| Operating Margin | -137.08% |
| Pretax Margin | -167.47% |
| Profit Margin | -170.59% |
| EBITDA Margin | -135.84% |
| EBIT Margin | -137.08% |
| FCF Margin | n/a |
Dividends & Yields
UroGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.43% |
| Shareholder Yield | -18.43% |
| Earnings Yield | -15.31% |
| FCF Yield | -12.84% |
Analyst Forecast
The average price target for UroGen Pharma is $28.50, which is 24.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $28.50 |
| Price Target Difference | 24.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 49.17% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
UroGen Pharma has an Altman Z-Score of -6.96 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.96 |
| Piotroski F-Score | 2 |